eFFECTOR Therapeutics, Inc. Warrant
EFTRW
EFTRW was delisted on the 2nd of July, 2024.
11 hedge funds and large institutions have $454K invested in eFFECTOR Therapeutics, Inc. Warrant in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
62% more capital invested
Capital invested by funds: $280K → $454K (+$175K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$6.82K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.58K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$167 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Aristeia Capital
Greenwich,
Connecticut
| $260K | -$6.82K | -42,602 | -3% |
|
2
Goldman Sachs
New York
| $86.4K | – | – | – |
|
|
WA
3
Whitebox Advisors
Minneapolis,
Minnesota
| $51.7K | – | – | – |
|
|
MI
4
MMCAP International
Grand Cayman,
Cayman Islands
| $25.3K | – | – | – |
|
|
PA
5
Parallel Advisors
San Francisco,
California
| $8.79K | – | – | – |
|
|
ICM
6
III Capital Management
Boca Raton,
Florida
| $7.25K | – | – | – |
|
|
TCM
7
Tenor Capital Management
New York
| $5.78K | – | – | – |
|
|
SOA
8
Sea Otter Advisors
Miami,
Florida
| $4.34K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $2.7K | +$3.15K | +19,692 | New |
|
|
WAM
10
Wolverine Asset Management
Chicago,
Illinois
| $2.32K | -$167 | -1,046 | -7% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $4 | – | – | – |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$3.58K | -27,743 | Closed |
|
EFTRW Hedge Fund Activity: Q2 2023 in Review
11 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q2 2023, worth a combined $454K — up 62% from $280K a quarter earlier.
Fund positioning in EFTRW was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $3.15K. The largest seller was Aristeia Capital, cutting an estimated $6.82K.
- 11 institutional investors held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $454K of eFFECTOR Therapeutics, Inc. Warrant stock for Q2 2023, up 62% quarter-over-quarter.
- 1 fund opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest eFFECTOR Therapeutics, Inc. Warrant buyer in Q2 2023 was UBS Group, an estimated $3.15K added.
- The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q2 2023 was Aristeia Capital, an estimated $6.82K sold.
Based on aggregated 13F filings for Q2 2023.